연구
연구업적
최근 5년 연구업적 현황
| 연도 | 2025년 | 2024년 | 2023년 | 2022년 | 2021년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 196편 | 179편 | 173편 | 163편 | 184편 |
| 공동 | 132편 | 147편 | 120편 | 115편 | 136편 | |
| 합계 | 328편 | 326편 | 293편 | 278편 | 320편 | |
3815. Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer.
Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, Hyung WJ, Wyrwicz L, Oh DY, Omori T, Moehler M, Garrido M, Oliveira SCS, Liberman M, Oliden VC, Smyth EC, Stein A, Bilici M, Alvarenga ML, Kozlov V, Rivera F, Kawazoe A, Serrano O, Heilbron E, Negro A, Kurland JF, Tabernero J; MATTERHORN Investigators.
N Engl J Med. 2025 Jul 17;393(3):217-230.
Link
3814. DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B.
Lee KW, Mahalingam D, Shim BY, Kim IH, Oh DY, Uronis H, Sym SJ, Sonbol M, Almhanna K, Tejani MA, Kang B, Kagey MH, Stilian M, Jia C, Sirard CA, Ajani JA, Klempner SJ.
Nat Commun. 2025 Jul 10;16(1):6393.
Link
3813. Immune-mediated adverse events in the randomized phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.
Antonuzzo L, Takahashi H, Park JO, Sookprasert A, Gillmore R, Yang SS, Cundom J, Petrova M, Vaccaro G, Holmblad M, Żotkiewicz M, Wang J, Rokutanda N, Oh DY.
Oncologist. 2025 Jul 4;30(7):oyaf148.
Link
3812. Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study.
Elimova E, Ajani J, Burris H, Denlinger CS, Iqbal S, Kang YK, Kim JH, Lee KW, Lin B, Mehta R, Oh DY, Rha SY, Seol YM, Yang L, Ozog MA, Garfin PM, Ku G.
Lancet Oncol. 2025 Jul;26(7):847-859.
Link
3811. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 study.
Cruz-Correa M, Xu RH, Moehler M, Oh DY, Kato K, Spigel D, Arkenau HT, Tabernero J, Zimina AV, Bai Y, Shi J, Lee KW, Hirano H, Wyrwicz L, Cid RP, Xu H, Sheng T, Barnes G.
Curr Med Res Opin. 2025 Jun;41(6):1007-1016.
Link
3810. Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial.
Meric-Bernstam F, Rha SY, Hamilton E, Kang YK, Hanna DL, Iqbal S, Lee KW, Lee J, Beeram M, Oh DY, Chaves J, Goodwin RA, Ajani JA, Yang L, Oza R, Elimova E.
Nat Commun. 2025 May 8;16(1):4293.
Link
3809. First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305.
Moehler M, Oh DY, Kato K, Arkenau T, Tabernero J, Lee KW, Rha SY, Hirano H, Spigel D, Yamaguchi K, Wyrwicz L, Disel U, Pazo-Cid RA, Fornaro L, Xu Y, Sheng T, Yang S, Kadva A, Cruz-Correa M, Xu RH.
Adv Ther. 2025 May;42(5):2248-2268.
Link
3808. Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02.
Oaknin A, Lee JY, Makker V, Oh DY, Banerjee S, González-Martín A, Jung KH, Ługowska I, Manso L, Manzano A, Melichar B, Siena S, Stroyakovskiy D, Fielding A, Puvvada S, Smith A, Meric-Bernstam F.
Adv Ther. 2025 May;42(5):2015-2018.
Link
3807. Investigational Use of Real-World Data as a Hybrid Control in Pancreatic Ductal Adenocarcinoma from the Randomized Phase Ib/II MORPHEUS Trial.
Ko AH, Oh DY, Lau J, Mhatre SK, Ci B, Machado R, Li S, Bretscher MT, Reyes-Rivera I, Zhu J, Zhang X, Patel J, Psioda MA, Ponz-Sarvise M.
Clin Pharmacol Ther. 2025 Apr;117(4):1021-1029.
Link
3806. Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.
Okines AFC, Curigliano G, Mizuno N, Oh DY, Rorive A, Soliman H, Takahashi S, Bekaii-Saab T, Burkard ME, Chung KY, Debruyne PR, Fox JR, Gambardella V, Gil-Martin M, Hamilton EP, Monk BJ, Nakamura Y, Nguyen D, O'Malley DM, Olawaiye AB, Pothuri B, Reck M, Sudo K, Sunakawa Y, Van Marcke C, Yu EY, Ramos J, Tan S, Bieda M, Stinchcombe TE, Pohlmann PR.
Nat Med. 2025 Mar;31(3):909-916.
Link